As checkpoint inhibitor-based immunotherapy strategies are emerging as one of the most promising cancer treatment tools for some drug-resistant tumors, we further explored the differences in immune checkpoint expression between the two groups, and observed significant differences in PDCD-1 (PD-1), CTLA4, LAG3, and BTLA expression (Fig. 6C). The gene discussed is LAG3; the disease is cancer.